• Explore /
  • Poster
  • / FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.

FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.

Abstract Poster

Authors

Kathleen Moore

Kathleen N. Moore

University of Oklahoma Health Sciences Center, Oklahoma City, OK

Kathleen N. Moore , Ignace Vergote , Ana Oaknin , Nicoletta Colombo , Susana N. Banerjee , Amit M. Oza , Patricia Pautier , Catherine Margaret Kelly , Karim S. Malek , Rodrigo Ruiz-Soto , Michael J. Birrer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02631876

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS5607)

DOI

10.1200/JCO.2017.35.15_suppl.TPS5607

Abstract #

TPS5607

Poster Bd #

425b

Abstract Disclosures

Similar Posters

First Author: Thomas J. Herzog

First Author: David M. O'Malley

First Author: Kathleen N. Moore

First Author: Thomas J. Herzog